Myriad Genetics, Inc.Myriad Genetics, Inc.Myriad Genetics, Inc.

Myriad Genetics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪506.21 M‬EUR
−3.65EUR
‪−122.97 M‬EUR
‪809.10 M‬EUR
‪88.35 M‬
Beta (1Y)
1.56
Employees (FY)
‪2.7 K‬
Change (1Y)
0
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Myriad Genetics, Inc.


CEO
Samraat S Raha
Website
Headquarters
Salt Lake City
Founded
1991
ISIN
US62855J1043
FIGI
BBG000KNHDH1
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Check out other big names from the same industry as MYD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Myriad Genetics, Inc. stocks are traded under the ticker MYD.
We've gathered analysts' opinions on Myriad Genetics, Inc. future price: according to them, MYD price has a max estimate of 15.43 EUR and a min estimate of 3.00 EUR. Watch MYD chart and read a more detailed Myriad Genetics, Inc. stock forecast: see what analysts think of Myriad Genetics, Inc. and suggest that you do with its stocks.
MYD reached its all-time high on Nov 6, 2000 with the price of 78.00 EUR, and its all-time low was 3.30 EUR and was reached on Aug 1, 2025. View more price dynamics on MYD chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Myriad Genetics, Inc. financials in yearly and quarterly reports right on TradingView.
Myriad Genetics, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MYD earnings for the last quarter are 0.04 EUR per share, whereas the estimation was −0.01 EUR resulting in a 742.59% surprise. The estimated earnings for the next quarter are −0.01 EUR per share. See more details about Myriad Genetics, Inc. earnings.
Myriad Genetics, Inc. revenue for the last quarter amounts to ‪180.90 M‬ EUR, despite the estimated figure of ‪171.36 M‬ EUR. In the next quarter, revenue is expected to reach ‪174.97 M‬ EUR.
MYD net income for the last quarter is ‪−280.56 M‬ EUR, while the quarter before that showed ‪−92.43 K‬ EUR of net income which accounts for ‪−303.43 K‬% change. Track more Myriad Genetics, Inc. financial stats to get the full picture.
No, MYD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 2, 2025, the company has ‪2.7 K‬ employees. See our rating of the largest employees — is Myriad Genetics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Myriad Genetics, Inc. EBITDA is ‪−15.20 M‬ EUR, and current EBITDA margin is −3.10%. See more stats in Myriad Genetics, Inc. financial statements.
Like other stocks, MYD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Myriad Genetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.